Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Human Urine Sample Collection for Alport Nephropathy Biomarker Studies

Terminated

Conditions: Alport Syndrome

First Posted Date: 2012-05-21

Last Posted Date: 2014-02-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT01602835

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Terminated

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma

Interventions: Drug: BYL719 as dispersible tablets (DT)
Drug: BYL719 as film-coated (FC) whole tablets
Biological: cetuximab
Drug: BYL719 drink suspension

First Posted Date: 2012-05-18

Last Posted Date: 2020-12-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 179

Registration Number: NCT01602315

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension

Phase 2

Completed

Conditions: Mild to Moderate Hypertension

Interventions: Drug: LCZ696
Drug: Sildenafil

First Posted Date: 2012-05-18

Last Posted Date: 2015-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT01601470

Locations: 🇩🇪
Novartis Investigative Site, Berlin, Germany

A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults

Phase 2

Completed

Conditions: Skeletal Muscle

Interventions: Drug: Placebo
Drug: BYM338

First Posted Date: 2012-05-18

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT01601600

Locations: 🇺🇸
Novartis Investigative Site, Brighton, Massachusetts, United States

Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment

Phase 2

Completed

Conditions: Chronic Idiopathic Urticaria

Interventions: Drug: placebo
Drug: IGE025

First Posted Date: 2012-05-16

Last Posted Date: 2015-03-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT01599637

Locations: 🇩🇪
Novartis Investigative Site, Muenster, Germany

Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion

Phase 3

Completed

Conditions: Branch Retinal Vein Occlusion

Interventions: Procedure: Laser
Drug: Ranibizumab

First Posted Date: 2012-05-16

Last Posted Date: 2016-11-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 455

Registration Number: NCT01599650

Locations: 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

Phase 3

Completed

Conditions: Renal Function
Liver Transplant

Interventions: Drug: Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.

First Posted Date: 2012-05-15

Last Posted Date: 2017-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT01598987

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: LCZ696
Drug: Olmesartan
Drug: Placebo

First Posted Date: 2012-05-15

Last Posted Date: 2015-10-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1161

Registration Number: NCT01599104

Locations: 🇯🇵
Novartis Investigative Site, Saitama, Japan

Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions

Phase 2

Terminated

Conditions: Neurogenic Urinary Bladder
Neurogenic Dysfunction of the Urinary Bladder
Neurogenic Bladder Disorder
Neurogenic Bladder, Spastic
Neurogenic Bladder, Uninhibited

Interventions: Drug: Placebo to SAF312
Drug: SAF312

First Posted Date: 2012-05-15

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT01598103

Locations: 🇨🇭
Novartis Investigative Site, Zürich, Switzerland

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Phase 1

Completed

Conditions: HER2 + Gastric Cancer
Esophageal Squamous Cell Carcinoma
HER2 + Breast Cancer
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: LJM716

First Posted Date: 2012-05-15

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT01598077

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
🇺🇸
University of Chicago Medical Center University of Chicago (16), Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital SC-5, Boston, Massachusetts, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy